CareDx reports Q3 EPS 28c, consensus 14c

Reports Q3 revenue $100.1M, consensus $95.3M. “We achieved record-setting third quarter 2025 financial results, a testament to our market leadership that has been established through a deep commitment to innovation and transplant patient care,” said John W. Hanna, President and CEO of CareDx (CDNA). “Our strategy to extend that leadership and deliver long-term profitable growth is guided by putting our customers at the center of everything we do, and we believe that strategy is working.”